- Original investigation
- Open Access
Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle
© van den Brom et al; licensee BioMed Central Ltd. 2010
- Received: 16 April 2010
- Accepted: 15 June 2010
- Published: 15 June 2010
In patients with myocardial infarction or heart failure, right ventricular (RV) dysfunction is associated with death, shock and arrhythmias. In patients with type 2 diabetes mellitus, structural and functional alterations of the left ventricle (LV) are highly prevalent, however, little is known about the impact of diabetes on RV characteristics. The purpose of the present study was to investigate whether LV changes are paralleled by RV alterations in a rat model of diabetes.
Zucker diabetic fatty (ZDF) and control (ZL) rats underwent echocardiography and positron emission tomography (PET) scanning using [18F]-2-fluoro-2-deoxy-D-glucose under hyperinsulinaemic euglycaemic clamp conditions. Glucose, insulin, triglycerides and fatty acids were assessed from trunk blood. Another group of rats received an insulin or saline injection to study RV insulin signaling.
ZDF rats developed hyperglycaemia, hyperinsulinaemia and dyslipidaemia (all p < 0.05). Echocardiography revealed depressed LV fractional shortening and tricuspid annular plane systolic excursion (TAPSE) in ZDF vs. ZL rats (both p < 0.05). A decrease in LV and RV insulin-mediated glucose utilisation was found in ZDF vs. ZL rats (both p < 0.05). LV associated with RV with respect to systolic function (r = 0.86, p < 0.05) and glucose utilisation (r = 0.74, p < 0.05). TAPSE associated with RV MRglu (r = 0.92, p < 0.05) and M-value (r = 0.91, p < 0.0001) and RV MRglu associated with M-value (r = 0.77, p < 0.05). Finally, reduced RV insulin-stimulated phosphorylation of Akt was found in ZDF vs. ZL (p < 0.05).
LV changes were paralleled by RV alterations in insulin-stimulated glucose utilisation and RV systolic function in a rat model of diabetes, which may be attributed to ventricular interdependence as well as to the uniform effect of diabetes. Since diabetic patients are prone to develop diabetic cardiomyopathy and myocardial ischaemia, it might be suggested that RV dysfunction plays a central role in cardiac abnormalities in this population.
- Left Ventricular
- Right Ventricular
- 18FDG Positron Emission Tomography
- Diabetic Cardiomyopathy
- Right Ventricular Function
Although been underestimated in the past, the contribution of right ventricular (RV) function to overall myocardial contractility is considerable. RV dysfunction is relevant in a variety of disease states, like pulmonary hypertension, coronary heart disease and heart failure. RV dysfunction is an independent predictor of outcome in patients with myocardial infarction  and heart failure [2, 3]. Patients with type 2 diabetes are at increased risk of myocardial infarction , however, not much is known on RV involvement in these patients.
While left ventricular (LV) impairment is a common complication of type 2 diabetes mellitus (T2DM), the number of studies focusing on the impact of T2DM on RV function is limited and conflicting [5–8]. We  and others [10, 11] have shown that alterations in LV energy metabolism, resulting from changes in substrate supply and utilisation, contribute to the development of myocardial dysfunction, but this association has not been established for the RV. Despite the association of RV dysfunction with aggravation of myocardial function and outcome in distinct cardiac diseases, its role in diabetic cardiomyopathy is unknown. The purpose of the present study was therefore to investigate whether LV changes are paralleled by RV alterations with respect to glucose utilisation and function in an experimental rat model of diabetes.
All experiments were approved by the Animal Care and Use Committee of the VU University, and were conducted following the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes, and the Dutch Animal Experimentation Act.
Male Zucker diabetic fatty (ZDF) rats (fa/fa; n = 12, Charles River Laboratories Brussels, Belgium) and age-matched Zucker lean control rats (ZL; +/+; n = 10) underwent echocardiography and positron emission tomography (PET) at 14 weeks of age. Trunk blood was collected for determinations of blood glucose, plasma insulin, fatty acid and triglyceride levels . Hearts were removed and either snap-frozen in dry-ice-chilled isopentane or fixed in 4% formalin for further biochemical and histological analysis.
Echocardiographic analyses were performed as previously described [9, 12]. Measured parameters for RV function were Doppler-derived cardiac output and tricuspid annular plane systolic excursion (TAPSE). Parameters for RV remodeling and pulmonary vascular remodeling were measured as RV end-diastolic diameter and pulmonary artery acceleration time normalised for cycle length (PAAT/cl), respectively . Further, estimated RV systolic pressure (eRVSP) was determined by 142*e(-11*[PAAT/cl]) .
Positron emission tomography
LV and RV glucose metabolism were measured using [18F]-2-fluoro-2-deoxy-D-glucose (18FDG) PET under hyperinsulinaemic euglycaemic clamp conditions, a gold-standard estimate of whole-body insulin sensitivity . Quantification was achieved with compartment analysis, based on a two-tissue compartment model .
Sections of LV and RV were stained with hematoxylin-eosin for determination of cardiomyocyte cross-sectional area . Picrosirius red staining was used for analysis of myocardial fibrosis. LV and RV fibrosis were expressed as the percentage tissue area positive for collagen, measured over minimally three randomly chosen areas per ventricle .
A separate group of rats (n = 4, ZDF rats; n = 4, ZL rats) received insulin stimulation (10 U·kg-1 BW insulin) or saline as control (n = 4, ZDF rats; n = 4, ZL rats) to study RV insulin signaling [9, 14] using the following primary antibodies: phospho-Akt-Ser473, phospho-GSK3β-Ser9, GSK3β (all Cell signaling Technology, Beverly, MA) and Akt2 (Upstate, Lake Placid, NY).
RV substrate metabolism was studied using glucose transporter 4 (GLUT4; Abcam, Cambridge, MA), phospho-AMP activated protein kinase (AMPK)-Thr172, AMPK (both Cell signaling Technology, Beverly, MA) and pyruvate dehydrogenase kinase-4 (PDK4; Santa Cruz Biotechnology, Santa Cruz, CA) . All signals were normalised to actin (Sigma, Saint Louis, Missouri) or total protein expression.
All data are presented as mean ± SEM. Group comparisons were performed using student t-test or two-way ANOVA with Bonferroni post-hoc analysis. Correlations were calculated by the Pearson's test. p < 0.05 was considered as statistically significant.
Characteristics of ZL (+/+) and ZDF (fa/fa) rats at 14 weeks of age
Body weight at killing [g]
335 ± 4
355 ± 8*
Non-fasting blood glucose [mmol·L-1]
5.0 ± 0.1
20.9 ± 0.8*
Fasting insulin [pmol·L-1]
116.9 ± 11.9
330.7 ± 69.6*
Fasting triglycerides [mmol·L-1]
0.36 ± 0.02
1.41 ± 0.20*
Fasting fatty acids [mmol·L-1]
0.16 ± 0.03
0.38 ± 0.08*
22.4 ± 1.0
8.9 ± 0.8*
RV and LV metabolic rates of glucose utilisation (MRglu) measured under hyperinsulinaemic euglycaemic conditions were decreased by 66% and 60%, respectively, in ZDF versus ZL rats (Figure 1C and 1D). RV MRglu was positively associated with LV MRglu (r = 0.74, p < 0.05, Figure 1F).
TAPSE associated significantly with RV MRglu (r = 0.92, p < 0.05) and M-value (r = 0.91, p < 0.0001) and RV MRglu associated significantly with M-value (r = 0.77, p < 0.05).
Glucose transporter 4 (GLUT4) and AMP-activated kinase (AMPK) protein expression was decreased in ZDF rats compared to ZL rats, however, GLUT4 failed to reach significance (p = 0.09, Figure 3E, F and 3H). Further, pyruvate dehydrogenase kinase 4 (PDK4) protein expression remained unchanged between the groups (Figure 3G).
Using echocardiography and 18FDG PET, the main finding of this study was that diabetic cardiomyopathy in an experimental model of diabetes is characterised by RV and LV alterations. In particular, changes in RV function were associated with systemic insulin sensitivity and reduced RV insulin-stimulated glucose utilisation. The alterations in RV and LV insulin-stimulated glucose metabolism and systolic function may be attributed to ventricular interdependence, but also indicate that diabetes similarly affects both ventricles.
Impaired RV systolic function as reported in the present study is in agreement with data from Mittal  and Movahed et al.  who reported comparable results in T2DM patients. Others showed deterioration of RV diastolic function in these patients, whereas the association with RV systolic dysfunction was undecided ambivalent [6, 7, 15]. In addition, the metabolic alterations in the RV as found in the present study are consistent with previously reported findings in 18FDG PET studies of the LV in ZDF rats [9, 16].
A restriction to glucose utilisation in the diabetic heart is the slow rate of glucose transport . In line with previous reports of the LV [9, 18, 19], decreased GLUT4 expression was found, which is compatible with the in vivo change in RV insulin-stimulated glucose metabolism. Impaired insulin signaling is associated with alterations in glucose metabolism. Impaired systemic and RV insulin sensitivity was demonstrated by hyperinsulinaemic euglycaemic clamp and an impaired ability of insulin to phosphorylate Akt and GSK3β. Overall these molecular analyses are in line with the molecular changes found in the LV , suggesting the uniform effect of diabetes on the heart. Finally, an association was found between RV and LV changes with respect to systolic function and glucose metabolism.
Remodeling of the ventricles was found to be different despite comparable changes in function and metabolism between the ventricles. Despite the absence of fibrosis in both ventricles, LV remodeling in ZDF rats is indicated by hypertrophy of individual cardiomyocytes in the absence of LV dilatation. In contrast, RV remodeling in ZDF rats is indicated by dilatation of the RV in the absence of hypertrophy. This is in agreement with Kosmala et al.  who reported the absence of changes in RV free wall thickness.
Briefly, the following mechanisms can be hypothesized: 1) increased LV filling pressure is translated to the pulmonary circulation, 2) ventricular interdependence and 3) both ventricles are exposed to the metabolic abnormalities characterising T2DM. Measurements on afterload and RV remodeling remained unchanged; we can therefore conclude that there are no differences in pulmonary vascular resistance. Based on the geometry of the heart it is expected that there is ventricular interdependence. However, in a model of diet-induced obesity, impaired LV function in the absence of RV dysfunction was found (data not shown), which suggests that the effect of diabetes on RV function may be of greater importance than previously assumed. In combination with the in vivo and molecular changes found in RV glucose metabolism and insulin signaling, this suggests that diabetes affects both ventricles.
Collectively, diabetes seems to affect RV glucose metabolism and RV systolic function in similar proportions as in the LV, which could be due to ventricular interdependence as well as the uniform effect of diabetes on the heart.
Whereas consequences of diabetes on the heart were previously restricted to the LV, this study showed that LV insulin-stimulated glucose utilisation and LV systolic function are paralleled by significant alterations in RV insulin-stimulated glucose utilisation and RV function in an experimental rat model of diabetes. RV dysfunction is associated with worse outcome in a variety of cardiovascular diseases, including myocardial infarction and heart failure. The negative association of RV function with prognosis has only been scarcely investigated in the diabetic population. However, since diabetic patients are prone to develop diabetic cardiomyopathy and myocardial ischaemia , it might be suggested that RV dysfunction plays a central role in cardiac abnormalities in this population. This warrants further research with respect to the role of RV function in diabetic cardiomyopathy and its relation to patient outcome in diabetes.
This work was supported by the Dutch Diabetes Research Foundation (grant 2003.00.029 and 2004.00.052) and EU-COST action BM0602.
- Mehta SR, Eikelboom JW, Natarajan MK, Diaz R, Yi C, Gibbons RJ, Yusuf S: Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol. 2001, 37: 37-43. 10.1016/S0735-1097(00)01089-5.View ArticlePubMedGoogle Scholar
- de Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise X, Ducloux G, Lablanche JM: Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol. 1998, 32: 948-954. 10.1016/S0735-1097(98)00337-4.View ArticlePubMedGoogle Scholar
- Di Salvo TG, Mathier M, Semigran MJ, Dec GW: Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995, 25: 1143-1153. 10.1016/0735-1097(94)00511-N.View ArticlePubMedGoogle Scholar
- Rytter L, Troelsen S, Beck-Nielsen H: Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care. 1985, 8: 230-234. 10.2337/diacare.8.3.230.View ArticlePubMedGoogle Scholar
- Mittal SR: Right ventricular functions in patients with type 2 diabetes below 50 years. J Assoc Physicians India. 2007, 55: 599-600.PubMedGoogle Scholar
- Kosmala W, Colonna P, Przewlocka-Kosmala M, Mazurek W: Right ventricular dysfunction in asymptomatic diabetic patients. Diabetes Care. 2004, 27: 2736-2738. 10.2337/diacare.27.11.2736.View ArticlePubMedGoogle Scholar
- Kosmala W, Przewlocka-Kosmala M, Mazurek W: Subclinical right ventricular dysfunction in diabetes mellitus--an ultrasonic strain/strain rate study. Diabet Med. 2007, 24: 656-663. 10.1111/j.1464-5491.2007.02101.x.View ArticlePubMedGoogle Scholar
- Movahed MR, Milne N: Presence of biventricular dysfunction in patients with type II diabetes mellitus. Congest Heart Fail. 2007, 13: 78-80. 10.1111/j.1527-5299.2007.888138.x.View ArticlePubMedGoogle Scholar
- van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, Molthoff CF, Lammertsma AA, Van der Velden J, Boer C: Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol. 2009, 8: 39-10.1186/1475-2840-8-39.PubMed CentralView ArticlePubMedGoogle Scholar
- Fang ZY, Prins JB, Marwick TH: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004, 25: 543-567. 10.1210/er.2003-0012.View ArticlePubMedGoogle Scholar
- An D, Rodrigues B: Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006, 291: H1489-H1506. 10.1152/ajpheart.00278.2006.View ArticlePubMedGoogle Scholar
- Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, Diamant M: Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia. 2005, 48: 1229-1237. 10.1007/s00125-005-1755-x.View ArticlePubMedGoogle Scholar
- Handoko ML, Schalij I, Kramer K, Sebkhi A, Postmus PE, van der Laarse WJ, Paulus WJ, Vonk-Noordegraaf A: A refined radio-telemetry technique to monitor right ventricle or pulmonary artery pressures in rats: a useful tool in pulmonary hypertension research. Pflugers Arch. 2008, 455: 951-959. 10.1007/s00424-007-0334-z.PubMed CentralView ArticlePubMedGoogle Scholar
- Ouwens DM, Diamant M, Fodor M, Habets DD, Pelsers MM, El Hasnaoui M, Dang ZC, van den Brom CE, Vlasblom R, Rietdijk A: Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia. 2007, 50: 1938-1948. 10.1007/s00125-007-0735-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Karamitsos TD, Karvounis HI, Dalamanga EG, Papadopoulos CE, Didangellos TP, Karamitsos DT, Parharidis GE, Louridas GE: Early diastolic impairment of diabetic heart: the significance of right ventricle. Int J Cardiol. 2007, 114: 218-223. 10.1016/j.ijcard.2006.02.003.View ArticlePubMedGoogle Scholar
- Shoghi KI, Gropler RJ, Sharp T, Herrero P, Fettig N, Su Y, Mitra MS, Kovacs A, Finck BN, Welch MJ: Time Course of Alterations in Myocardial Glucose Utilization in the Zucker Diabetic Fatty Rat with Correlation to Gene Expression of Glucose Transporters: A Small-Animal PET Investigation. J Nucl Med. 2008, 49: 1320-1327. 10.2967/jnumed.108.051672.PubMed CentralView ArticlePubMedGoogle Scholar
- Slot JW, Geuze HJ, Gigengack S, James DE, Lienhard GE: Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci USA. 1991, 88: 7815-7819. 10.1073/pnas.88.17.7815.PubMed CentralView ArticlePubMedGoogle Scholar
- Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Van Arsdall M, Adrogue JV, Brown KK, Swaney JS: Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab. 2005, 289: E328-E336. 10.1152/ajpendo.00055.2005.View ArticlePubMedGoogle Scholar
- Pelzer T, Jazbutyte V, Arias-Loza PA, Segerer S, Lichtenwald M, Law MP, Schafers M, Ertl G, Neyses L: Pioglitazone reverses down-regulation of cardiac PPARgamma expression in Zucker diabetic fatty rats. Biochem Biophys Res Commun. 2005, 329: 726-732. 10.1016/j.bbrc.2005.02.029.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.